{
    "N/R/U": null,
    "Applicant": "Kite Pharma Inc.",
    "BLA Number": "125703",
    "Proprietary Name": "Tecartus",
    "Proper Name": "Brexucabtagene Autoleucel",
    "BLA Type": "351(a)",
    "Strength": "2\u00d710^6 CAR-positive viable T cells per kg body weight ",
    "Dosage Form": "For Injection",
    "Route of Administration": "Intravenous",
    "Product Presentation": "Bag",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "July 24, 2020",
    "Ref. Product Proper Name": " ",
    "Ref. Product Proprietary Name": " ",
    "Supplement Number": "0",
    "Submission Type": "Original",
    "License Number": "2064",
    "Product Number": "001",
    "Center": "CBER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "October 01, 2028",
    "drug": [
        {
            "name": "Brexucabtagene Autoleucel",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15699"
        }
    ]
}